Thor Medical ASA's next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2022, Thor Medical ASA has 119.10M shares outstanding.
| Shares Outstanding | 119.10M |
As of June 30, 2022, Thor Medical ASA maintains a current ratio of 2.50, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is - -, indicating a certain level of leverage, while an interest coverage ratio of -1,369.64 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.50 |
| Quick Ratio | 2.32 |
| Interest Coverage | -1,369.64 |
Over the twelve months ended June 30, 2022, Thor Medical ASA posted a negative return on equity (ROE) of -155.90, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -107.68, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 39.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -155.90 |
| Return on Assets (ROA) | -107.68 |
| Employee Count | 39.00 |
Over the twelve months ended June 30, 2022, Thor Medical ASA recorded 1.16M in income tax expense. The company reported a pretax loss of -432.98M and -434.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 1.16M |
As of the close on October 15, 2026, Thor Medical ASA's stock has gained approximately 25.11% over the past 52 weeks.
| 52-Week Price Change | 25.11% |
| 50-Day Moving Average | 4.94 |
Over the twelve months ended June 30, 2022, Thor Medical ASA generated - - in revenue and converted that into -434.14M in net income, yielding earnings per share of -4.01. EBITDA reached -430.07M, while operating income came in at -440.49M.
| Operating Income | -440.49M |
| Pretax Income | -432.98M |
| Net Income | -434.14M |
| EBITDA | -430.07M |
| EBIT | -440.49M |
| Earnings Per Share (EPS) | -4.01 |
As of June 30, 2022, Thor Medical ASA holds 287.44M in cash and equivalents against - - in total debt, resulting in a net debt position of -287.44M. Total book value stands at 182.55M, with working capital of 185.85M providing operational flexibility.
| Cash & Cash Equivalents | 287.44M |
| Net Debt | -287.44M |
| Equity (Book Value) | 182.55M |
| Book Value Per Share | 1.53 |
| Working Capital | 185.85M |
Thor Medical ASA produced -393.65M in operating cash flow over the twelve months ended June 30, 2022. After subtracting -150,000.00 in capital expenditures, free cash flow totaled -393.80M - equivalent to -3.63 per share.
| Operating Cash Flow | -393.65M |
| Capital Expenditures | -150,000.00 |
| Free Cash Flow | -393.80M |
| FCF Per Share | -3.63 |
Thor Medical ASA's most recent stock split took place on June 19, 2025.
| Last Split Date | 6/19/2025 |
Already premium?